In conclusion, our data suggest that the ICI- and antiangiogenesis-based neoadjuvant/conversion therapy has good efficacy and feasibility in cT4a/bN+ gastric cancer, especially the MSI-H and PD-L1 positive patients. The gene discussed is CD274; the disease is gastric cancer.